This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
|
|
- Muriel Walton
- 6 years ago
- Views:
Transcription
1 abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical study report had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion. The synopsis may include approved and non approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities. A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country.. Additional information on this study and the drug concerned may be provided upon request based on s Policy on Transparency and Publication of Clinical Study Data. The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of.
2 1 of NOV / 23 NOV JUN 2008 Title of trial: Telmisartan Randomized AssessmeNt Study in ace intolerant subjects with cardiovascular Disease (TRANSCEND) Coordinating Investigator: A large, simple, randomized, double-blind, multicentre, international trial comparing the effects of telmisartan with placebo on outcomes in patients at high risk for cardiovascular events and intolerant of ACE-I Trial sites: Multicentre study, cf. Appendix Publication (reference): Clinical phase: Objectives: Methodology: TRANSCEND Investigators. Lancet 2008;372: [P ] Department of error. Erratum for: 'TRANSCEND Investigators. Lancet 2008;372: '. Lancet 2008;372(9647): 1384 [P ] Sleight P. Acta Diabetol 2005;42:S50-S56 [P ] ONTARGET/TRANSCEND Investigators. Am Heart J 2004;148(1):52-61 [P ] III The objective of the TRANSCEND trial was to determine if telmisartan 80 mg daily is superior to placebo in reducing the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke and hospitalisation for congestive heart failure (CHF) in patients who are intolerant to angiotensin converting enzyme-inhibitors (ACE-Is). Randomised (1:1 ratio), double-blind, parallel-group, placebo-controlled trial with a single-blind run-in phase of 3 to 4 weeks (starting with placebo for 1 week, continuing with telmisartan 80 mg for 2 to 3 weeks), and a planned randomised treatment phase of 3.5 to 6 years; patients were randomised to either monotherapy with telmisartan (80 mg) or to placebo. All patients in this trial received concomitant medication according to their medical needs.
3 2 of 12 No. of subjects: planned: entered: at least 5000 patients as per original trial protocol at least 6000 patients as per Amendment 2.1 (dated 17 April 2003) actual: Diagnosis and main criteria for inclusion: enrolled (run-in period): 6665 patients entered (randomised period): 5926 patients Telmisartan: entered: 2954 patients; analysed (for primary endpoint): 2954 patients Placebo: entered: 2972 patients; analysed (for primary endpoint): 2972 patients Male or female patients, 55 years of age or older, and at a high risk of CV events indicated by: 1. Coronary artery disease (CAD) defined as: a) Previous MI (>2 days post uncomplicated MI, prior to informed consent), or b) Stable or unstable angina (>30 days prior to informed consent) each with documented multi-vessel coronary disease, >50% stenosis in at least 2 major coronary arteries on coronary angiography, or positive stress test (ST depression 2 mm or a positive nuclear perfusion scintigram), or c) Multi-vessel percutaneous transluminal coronary angioplasty (PTCA) >30 days prior to informed consent, or d) Multi-vessel coronary artery bypass graft (CABG) surgery without angina (>4 years prior to informed consent), or with recurrent angina following surgery. 2. Peripheral arterial disease (PAD) defined as: a) Previous limb bypass surgery or percutaneous transluminal angioplasty, or b) Previous limb or foot amputation, or c) History of intermittent claudication, with an ankle/arm blood pressure (BP) ratio of 0.80 on at least one side, or d) Significant peripheral artery stenosis (>50%) documented by angiography on non-invasive testing. 3. Previous stroke (including definite or presumed cerebral infarction, intracerebral haemorrhage, stroke of uncertain subtype, but not subarachnoid haemorrhage).
4 3 of Transient ischaemic attack (TIA) >7 days and <1 year prior to informed consent (TIA defined as acute loss of focal cerebral or monocular function with symptoms lasting <24 hours, and thought to be due to inadequate cerebral or ocular blood supply as a result of arterial thrombosis or embolism). Test product: 5. High-risk diabetes (insulin-dependent or non-insulin-dependent) with evidence of end-organ damage (retinopathy, left ventricular hypertrophy, or any evidence of previous cardiac or vascular disease). Only patients with known intolerance to ACE-Is according to their medical history or as assessed during the run-in period of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) were included into this trial. Telmisartan dose: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: telmisartan 80 mg daily mode of admin.: Oral batch no.: Refer to Appendix Reference therapy: Telmisartan-matching placebo dose: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: placebo matching telmisartan 80 mg mode of admin.: Oral batch no.: Refer to Appendix Duration of treatment: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: planned: minimum of 3.5 years, maximum of 6 years actual median observation time: telmisartan: 1766 days placebo: 1772 days
5 4 of 12 Criteria for evaluation: Efficacy / clinical pharmacology: Primary endpoint: Composite of CV death, MI, stroke, or hospitalisation for CHF Secondary endpoints: - Composite of CV death, non-fatal MI, and non-fatal stroke - The individual components of the primary endpoint - Occurrence of nephropathy analysed based on the following 6 subcategories: Doubling of serum creatinine Progression to end-stage renal disease [ESRD] (i.e. initiation of dialysis, need for renal transplantation, or estimated glomerular filtration rate [egfr] <15 ml/min/1.73m 2 ) New microalbuminuria (urinary albumine creatinine ratio [UACR] 30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline) New macroalbuminuria (UACR 300 mg/g Crea in patients with a UACR <300 mg/g Crea at baseline) Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria Normalisation from micro- or macroalbuminuria to normoalbuminuria (UACR <30 mg/g Crea in patients with a UACR 30 mg/g Crea at baseline) - Newly diagnosed CHF - CV revascularisation procedures - Newly diagnosed diabetes - Cognitive impairment and cognitive decline - New onset of atrial fibrillation Other endpoints: - All-cause mortality (= non-cv mortality + CV mortality) Non-CV death - Angina (unstable, new, and worsening) - TIA - Malignancy (fatal and non-fatal) - Laser therapy for diabetic retinopathy
6 5 of 12 Additionally, changes from baseline in BP, ankle/arm BP ratio, Mini Mental State Examination (MMSE), egfr, serum creatinine, and UACR were determined. Safety: Statistical methods: Serious adverse events (SAEs, coded using the Medical Dictionary for Regulatory Activities [MedDRA]), adverse events (AEs) leading to discontinuation of trial medication (coded using an internal coding system); clinical laboratory evaluations; vital signs (BP and pulse rate), electrocardiograms [ECGs]. Primary and secondary outcome events: time-to-event analysis (Kaplan Meier) and hazard ratios based on the intent-to-treat principle and using the proportional hazard model (Cox regression); χ 2 -test for cognitive impairment and cognitive decline Sensitivity analyses: Cox regression including covariates, χ 2 -test Descriptive statistics, analysis of covariance (ANCOVA) SUMMARY CONCLUSIONS: Efficacy / clinical pharmacology results: A total of 6665 patients were enrolled by 650 centres worldwide. After a singleblind run-in period of 3 to 4 weeks, a total of 5926 patients were randomised to either telmisartan 80 mg (2954 patients) or placebo (2972 patients). All patients received concomitant medication according to their medical needs. The most frequent reasons for non-randomisation were the patients' request to stop treatment (6.1%), insufficient compliance with study medication (5.1%), and the occurrence of AEs (2.6%). The majority of patients (99.7% of randomised patients) completed the trial with identical proportions in the 2 treatment groups; 'completed' was defined as final visit performed or vital status confirmed (including death) at the end of the trial. A total of 18.5% of all randomised patients permanently discontinued study medication (telmisartan: 17.7%; placebo: 19.4%) with a trend for fewer discontinuations in the telmisartan group (risk ratio for telmisartan vs. placebo: 0.91; 95% CI 0.82, 1.02; p=0.0969). Of those who permanently discontinued study medication, 42.9% stopped due to AEs (telmisartan: 47.2%; placebo: 39.1%). Demographics and baseline characteristics of the randomised patients were similar in the 2 treatment groups. The mean age of patients was 66.9 years;
7 6 of % of patients were male. Most patients were of white ethnicity (62.4%); 21.3% of patients were Asian, and 1.8% were black. For the majority of patients, CAD was the primary risk factor for inclusion in the trial (66.8%). At baseline, hypertension was present in 86.0% of patients and diabetes mellitus in 41.6%. The majority of patients received acetylsalicylic acid (74.7% at baseline, 71.2% at study end), beta blockers (58.3% at baseline, 57.8% at study end), and statins (55.2% at baseline, increasing to 63.5% at study end). After randomisation, differences between treatment groups in the use of concomitant medication were seen for diuretics (33.0% at baseline, 33.7% at study end in the telmisartan group, 40.0% at study end in the placebo group), calcium channel blockers excluding diltiazem/verapamil (31.1% at baseline, 30.8% vs. 39.2%, respectively, at study end), and beta blockers (58.3% at baseline, 56.6% vs. 59.0%, respectively, at study end). The mean systolic/diastolic blood pressure (SBP/DBP) at baseline was 141.0/81.9 mmhg and did not differ between treatment groups. During the runin period, patients received telmisartan-matching placebo for 1 week, followed by telmisartan 80 mg for 2 to 3 weeks. When patients were randomised following the run-in period, the mean SPB/DPB had decreased similarly in both treatment groups (telmisartan: 5.9/ 4.0 mmhg, placebo: 6.1/ 4.0 mmhg). At the 6 week visit, the BP in the telmisartan group had further decreased (mean change from baseline: 7.2/ 4.8 mmhg) while it had almost returned to baseline levels in the placebo group (mean change from baseline: 1.0/ 1.2 mmhg). These treatment differences in BP were generally maintained throughout the study. The weighted mean change from baseline post-randomisation was 6.5/ 4.9 mmhg with telmisartan and 2.3/ 2.6 mmhg with placebo. At baseline, no differences between treatment groups were observed for the mean egfr, mean serum creatinine, or geometric mean UACR. Patient compliance with study medication during the randomised period was high at all visits. At the final visit, 79.2% of patients in the telmisartan group and 77.1% in the placebo group were compliant with study medication. Primary endpoint The primary composite endpoint occurred in 465 patients (15.7%) in the telmisartan group and 504 patients (17.0%) in the placebo group; the event rates per 100 patient years were 3.58 and 3.87, respectively. The hazard ratio (HR) of telmisartan vs. placebo was 0.92 (95% CI 0.81, 1.05; p = ). The trial could not demonstrate superiority of telmisartan over placebo in the prevention of CV
8 7 of 12 death, non-fatal MI, non-fatal stroke, and hospitalisation for CHF. For non-fatal stroke and non-fatal MI, incidences were lower in the telmisartan group than in the placebo group (non-fatal MI: 3.6% vs. 4.6%, non-fatal stroke: 3.6% vs. 4.3%); no relevant differences were seen for hospitalisation for CHF and CV death. Baseline SBP and SBP changes over time did not substantially influence the results for the primary endpoint; the SBP-adjusted hazard ratio of telmisartan vs. placebo was 0.94 (95% CI 0.83, 1.07). The TRANSCEND trial had been planned based on the event rates observed in the previous Heart Outcomes Prevention Evaluation (HOPE) trial. Under these assumptions, a sample size of 3000 patients per treatment group to be recruited within 2 years and to be observed for a maximum of 5.5 years would have had a power of approximately 94% to establish the superiority of telmisartan over placebo. However, the observed yearly event rates in TRANSCEND were lower than expected. This was mainly due to the improved standard of medical care at the time the TRANSCEND trial was performed, which was reflected e.g. in the more frequent use of concomitant medications and of revascularisation procedures in patients in TRANSCEND. According to a retrospective power calculation with the number of patients randomised and the actual recruitment and observation periods and assuming that the observed event rates are real, the TRANSCEND study had a limited statistical power and as such only a 25% chance of demonstrating superiority of telmisartan over placebo. The Kaplan-Meier analysis suggested that the assumption of proportional hazards was not fulfilled for the primary composite endpoint as well as for the secondary composite endpoint of CV death, MI, and stroke. Hence, this was investigated using a Cox proportional hazards model with the categorised time to first event ( 6 months, >6 months) as covariate. No treatment difference was seen for the primary endpoint up to 6 months after randomisation. Thereafter (>6 months), the incidence of the primary endpoint was lower in the telmisartan group than in the placebo group (13.6% vs. 15.2%). However, the interaction between treatment and time period was not statistically significant (p = ). The per-protocol set (PPS) included all patients of the full analysis set (FAS) who were taking study medication according to the trial protocol for the majority of their time in the study. The per-protocol analysis showed the consistency and confirmed the results obtained for the FAS; the hazard ratio of telmisartan vs. placebo for the primary endpoint was 0.95 (95% CI 0.82, 1.08). The incidences observed with the PPS were slightly lower than in the FAS, suggesting that
9 8 of 12 persistent use of study medication had a beneficial effect. A total of 30 subgroup analyses were performed for the primary endpoint, e.g. for core subgroups such as age, intrinsic factors, extrinsic factors, medical history, and concomitant medication use. No significant subgroup-by-treatment interactions were observed for the primary endpoint. Secondary and other endpoints The incidence of the secondary 3-fold composite endpoint of CV death, nonfatal MI, and non-fatal stroke, which was the primary endpoint in the HOPE study, was significantly lower in the telmisartan group (13.0%) than in the placebo group (14.8%). The hazard ratio for this comparison was 0.87 (95% CI 0.76, 1.00; p = ). For the 3-fold composite endpoint, the treatment difference was not consistent over time (time period-by-treatment interaction: p = ). No treatment difference was seen up to 6 months after randomisation. Thereafter (<6 months), the incidences of the 3-fold composite endpoint were significantly lower with telmisartan (11.3%) than with placebo (13.6%); the hazard ratio was 0.82 (95% CI 0.71, 0.95). The SBP-adjusted hazard ratio of telmisartan vs. placebo was 0.88 (95% CI 0.77, 1.01). The incidences of the 3-fold composite endpoint for the PPS were slightly lower than for the FAS; the hazard ratio of telmisartan vs. placebo based on the PPS was 0.89 (95% CI 0.77, 1.03). The incidence of all-cause mortality was 12.3% in the telmisartan group and 11.7% in the placebo group. The hazard ratio of telmisartan vs. placebo was 1.05 (95% CI 0.91, 1.22). The predominant reasons for death were CV death and malignancies. Telmisartan significantly reduced the risk of new microalbuminuria (HR 0.76), new macroalbuminuria (HR vs. placebo 0.66), of the composite of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria (HR 0.80), and had a beneficial treatment effect on the normalisation from micro- or macro- to normoalbuminuria (HR 1.39). The incidences for the doubling of serum creatinine were 2.1% in the telmisartan group and 1.3% in the placebo group; the hazard ratio of telmisartan vs. placebo of 1.58 was statistically significant. No treatment difference was observed for progression to ESRD. The incidence of newly diagnosed diabetes did not differ between treatment groups. The incidence of confirmed newly diagnosed diabetes (as assessed by
10 9 of 12 the investigators) was significantly lower with telmisartan than with placebo (HR 0.75, 95% CI 0.60, 0.95). In this trial, a higher rate of malignancies (overall and in patients without cancer at baseline) was observed in patients treated with telmisartan than in those treated with placebo. No differences between treatment groups were seen for fatal malignancies. So far, there is no evidence that ARBs are associated with a higher risk of malignancies. Chance findings due to multiple testing cannot be excluded. Safety results: The mean observation time during the run-in period was 25.2 days. During the randomised period, the overall mean observation time was about 4.6 years and comparable between treatment groups. While receiving the study medication (on treatment), the mean observation time was 1527 days in the telmisartan group and 1515 days in the placebo group. All differences between treatment groups described below for AEs were also observed after adjustment for observation time. Since the safety profile of telmisartan is well established, reporting of AEs was limited to AEs leading to permanent treatment discontinuation and SAEs. During the run-in period, study drug-related AEs leading to permanent treatment discontinuation were reported for 2.54% of patients. The most frequent AE leading to permanent treatment discontinuation was dizziness / vertigo / lightheadedness (0.68%). Serious adverse events leading to permanent treatment discontinuation during the run-in period were reported for only 7 patients (0.11%), with hypotension (n=3) being the most frequently reported. Non-fatal SAEs were reported for 1.83% of patients during the run-in period; these were mainly cardiac disorders. During the randomised period, 12.03% of patients died. Mortality overall and mortality while on treatment were slightly higher in the telmisartan group than in the placebo group (overall: 12.32% vs %; on treatment: 9.61% vs. 8.95%). However, when all-cause mortality was analysed as a secondary efficacy endpoint, no statistically significant difference between telmisartan and placebo was observed (HR 1.05; 95% CI 0.91, 1.22). The most frequently reported SAEs on treatment in association with death were sudden cardiac death (telmisartan: 2.34%; placebo: 2.25%) and myocardial infarction (telmisartan: 1.18%; placebo: 1.18%). The frequencies of primary causes of death and of SAEs reported in association with death while on treatment were generally comparable between treatment groups. The incidence of cardiac failure reported as SAE in association
11 10 of 12 with death was higher in the telmisartan group (0.91%) than in the placebo group (0.64%). The incidence of ventricular tachyarrhythmia was higher in the telmisartan group (0.20%) than in the placebo group (0.03%). Post-treatment, primary causes of death and SAEs in association with death were observed at comparable frequencies in both treatment groups. The frequencies of patients with non-fatal SAEs reported while on treatment were comparable between the 2 treatment groups (telmisartan: 57.24%; placebo: 58.51%). The frequencies of SAEs were also generally comparable between treatment groups on the system organ class and preferred term levels. However, SAEs belonging to the system organ class cardiac disorders were reported in fewer patients in the telmisartan group (24.51%) than in the placebo group (26.62%). The following preferred terms were reported in slightly fewer patients in the telmisartan group than in the placebo group: diabetes mellitus (6.60% vs. 8.04%), angina pectoris (14.15% vs %), and myocardial infarction (4.67% vs. 5.42%). In contrast, the preferred term intermittent claudication was slightly more frequently reported in the telmisartan group than in the placebo group (6.70% vs. 5.65%). The frequency of SAEs considered drug-related by investigators was low. Serious adverse events considered study drug-related by investigators were reported for 0.44% of patients in the telmisartan group and in 0.13% of patients in the placebo group. Adverse events leading to permanent treatment discontinuation were slightly more frequent in the telmisartan group (8.36%) than in the placebo group (7.57%). The most frequently reported AE leading to permanent treatment discontinuation was hypertension / higher blood pressure / uncontrolled high BP; it was less frequently reported in the telmisartan group (0.61%) than in the placebo group (1.01%). In contrast, hypotension / low BP (telmisartan: 0.71%; placebo: 0.37%) and dizziness / vertigo / lightheadedness (telmisartan: 0.74%; placebo: 0.30%) were more frequently reported in the telmisartan group than in the placebo group. As expected, further differences between the treatment groups were observed for other known side effects of telmisartan: Gastrointestinal symptoms, renal diseases, and increases in creatinine or potassium values were more frequently reported as AEs leading to permanent treatment discontinuation in the telmisartan group than in the placebo group. Discontinuations of trial medication because of non-fatal SAEs were rare (telmisartan: 0.34%; placebo: 0.24%). Cough, angioedema, hypotensive symptoms, syncope, diarrhoea, renal failure, and signs of renal dysfunction were defined post hoc as AEs of special interest.
12 11 of 12 The differences between treatment groups were analysed using the χ 2 -test. For this analysis, patients were considered if a respective SAE was documented, a respective reason for temporary or permanent treatment discontinuation was given, or, in the case of signs of renal dysfunction, if relevant clinical laboratory values were above a pre-specified limit. Overall, this analysis confirmed the established safety profile of telmisartan: For cough, angioedema, and renal failure, no relevant differences between telmisartan and placebo were observed, whereas hypotensive symptoms, syncope, diarrhoea, and signs of renal dysfunction were more frequent in the telmisartan group than in the placebo group. The difference seen for signs of renal dysfunction was mainly due to higher frequencies of patients with potassium values >5.5 mmol/l, with doubling of serum creatinine, and with temporary or permanent discontinuation of study medication due to renal dysfunction in the telmisartan group; the frequency of patients with need for dialysis was comparable between treatment groups. Mean increases in serum creatinine from baseline to the end of the study were higher in the telmisartan group (0.06 mg/dl) than in the placebo group (0.01 mg/dl). The proportions of patients with transitions from low or normal to high creatinine values (telmisartan: 16.6%; placebo: 11.6%) and with possibly clinically significant increases ( 1.5 mg/dl) in creatinine (telmisartan: 13.8%; placebo: 11.2%) were higher in the telmisartan group than in the placebo group. For serum potassium, a small mean increase from baseline was observed in the telmisartan group (0.05 mmol/l), whereas a small mean decrease was observed in the placebo group ( 0.07 mmol/l). The frequency of patients with transitions from low or normal to high potassium values was higher in the telmisartan group (3.6%) than in the placebo group (2.0%). Likewise, possibly clinically significant increases of serum potassium (>5.8 mmol/l) at any time were more frequent in the telmisartan group (1.8%) than in the placebo group (0.5%). For the remaining laboratory parameters investigated (total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, glucose), no relevant differences were observed between treatment groups. The analyses of AEs and clinical laboratory parameters in subgroups did not reveal unexpected differences from the overall study population. The frequencies of patients with markedly low BP (evaluated as sitting SBP <100 mmhg, sitting DBP <60 mmhg, or both sitting SBP <100 and DBP
13 12 of 12 <60 mmhg) were higher in the telmisartan group than in the placebo group throughout the randomised period. Between treatment groups, no relevant differences in ECG data were noted. Conclusions: The TRANSCEND study could not demonstrate that telmisartan was superior to placebo in reducing the 4-fold composite endpoint of CV death, non-fatal MI, non-fatal stroke, and hospitalisations for CHF in patients at high risk and intolerant to ACE-Is who received concomitant medication according to their medical needs and current medical guidelines. Telmisartan was shown to be superior to placebo in reducing the secondary 3-fold composite endpoint of CV death, non-fatal MI, and non-fatal stroke, which was the primary endpoint in the HOPE study. The treatment benefit of telmisartan observed for the 3-fold composite endpoint was due to lower incidences of the components 'non-fatal stroke' and 'non-fatal MI' in the telmisartan group. The treatment effect of telmisartan on the 3-fold composite endpoint was time-dependent, with a significant treatment benefit of telmisartan from 6 months after randomisation onwards. Overall, the established safety profile of telmisartan was confirmed also in patients at high risk of cardiovascular disease.
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationSynopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable
Synopsis Study title Investigational Product Indication Design of clinical trial Number of trial sites Duration of clinical trial / Timetable Repetitive levosimendan infusions for patients with advanced
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationMedication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial
Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators
More informationMedication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial
Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Inspra / Eplerenone
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationChronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationTable S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationEDMS #4298 Version 1.0
Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55 REVEAL) Data Analysis Plan Version 1.0 1 Table of Contents 1 VERSION HISTORY... 2 2 INTRODUCTION... 3 2.1 BACKGROUND...
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationLowering blood pressure (BP) in patients with type 2
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial William B. White, MD; Fatima Jalil, MD;
More informationPresented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer
Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More information